000			01967 a2200577 4500
005			20250516213133.0
264		0	_c20140610
008			201406s 0 0 eng d
022			_a1533-4406
024	7		_a10.1056/NEJMoa1402582 _2doi
040			_aNLM _beng _cNLM
100	1		_aKing, Talmadge E
245	0	0	_aA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. _h[electronic resource]
260			_bThe New England journal of medicine _cMay 2014
300			_a2083-92 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Oral
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntifibrinolytic Agents _xadverse effects
650	0	4	_aDisease Progression
650	0	4	_aDouble-Blind Method
650	0	4	_aEnzyme Inhibitors _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIdiopathic Pulmonary Fibrosis _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPyridones _xadverse effects
650	0	4	_aTreatment Outcome
650	0	4	_aVital Capacity _xdrug effects
700	1		_aBradford, Williamson Z
700	1		_aCastro-Bernardini, Socorro
700	1		_aFagan, Elizabeth A
700	1		_aGlaspole, Ian
700	1		_aGlassberg, Marilyn K
700	1		_aGorina, Eduard
700	1		_aHopkins, Peter M
700	1		_aKardatzke, David
700	1		_aLancaster, Lisa
700	1		_aLederer, David J
700	1		_aNathan, Steven D
700	1		_aPereira, Carlos A
700	1		_aSahn, Steven A
700	1		_aSussman, Robert
700	1		_aSwigris, Jeffrey J
700	1		_aNoble, Paul W
773	0		_tThe New England journal of medicine _gvol. 370 _gno. 22 _gp. 2083-92
856	4	0	_uhttps://doi.org/10.1056/NEJMoa1402582 _zAvailable from publisher's website
999			_c23833185 _d23833185